Q&A: Building A Burgeoning Advanced Therapy Infrastructure In The Middle East

BioProcess Insider reported on a newly announced partnership between Burjeel Holdings and Caring Cross aimed at expanding access to chimeric antigen receptor (CAR)-T cell therapies in the United Arab Emirates (UAE). This collaboration marks a significant step toward making advanced therapies more accessible in the broader Middle East and North Africa (MENA) region.

To provide deeper insight into the current landscape and future potential of advanced therapies in MENA, Dr. Boro Dropulić, Executive Director of Caring Cross, shared his perspective on regional challenges, opportunities for innovation, and the role of global partnerships in accelerating progress.

The following interview has been lightly edited for clarity and brevity.